5 Short Squeeze Candidates To Watch This Week: Aterian, Harbor Custom Development Remain At The Top, Veru JoinsBenzinga • 05/02/22
LIXTE Biotechnology Announces the Closing of $5.8 Million Registered Direct Offering Priced At-The-MarketGlobeNewsWire • 04/14/22
WallachBeth Capital Announces Completion of LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) $5.8 Million Registered Direct OfferingPRNewsWire • 04/14/22
WestPark Capital Announces Completion of $5.8 Million Registered Direct Offering Priced At-The-Market for Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT)Business Wire • 04/13/22
WallachBeth Capital Announces Purchase and Sale of LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT)PRNewsWire • 04/13/22
Biotech Stocks News: What's Going on With LIXT, PTE, QLGN and ATNM Stocks Today?InvestorPlace • 04/12/22
LIXTE Biotechnology Announces $5.8 Million Registered Direct Offering Priced At-The-MarketGlobeNewsWire • 04/12/22
Lixte Biotech Shares Jumps Over 100% On Promising Preclinical Data From Lead Program In KRAS-Mutant CancersBenzinga • 04/12/22
LIXTE Biotechnology Announces Preclinical Results of its Collaboration with the Netherlands Cancer Institute, Revealing Striking Anti-Cancer Activity of LB-100 In Novel Drug CombinationsGlobeNewsWire • 04/12/22
Inactivating Mutations in Scaffold Component of PP2A, the Target Enzyme of LIXTE Biotechnology's Clinical Compound LB-100, are Associated with Exceptionally Long Survival of Patients with Ovarian Clear Cell Cancer Treated with ImmunotherapyGlobeNewsWire • 03/22/22
LIXTE Biotechnology Holdings, Inc. to Present at MedInvest Pharmaceutical and Biotechnology Investor ConferenceGlobeNewsWire • 03/16/22
Lixte Biotechnology Announces Filing of First Patent Application Resulting from Collaboration with the Netherlands Cancer Institute and the Oncode Institute to Identify the Most Promising Drug Combinations for Lead Clinical Compound, LB-100GlobeNewsWire • 01/12/22
Lixte Biotechnology's LB-100 Reported to Convert Immunologically Unresponsive (“Cold”) Tumors to Immunologically Responsive (“Hot”) TumorsGlobeNewsWire • 01/05/22
LIXTE BIOTECHNOLOGY HOLDINGS, INC. ANNOUNCES THAT ENROLLMENT HAS RESUMED IN NATIONAL CANCER INSTITUTE'S TRIAL TO DETERMINE ABILITY OF LIXTE COMPOUND LB-100 TO ENTER RECURRENT, MALIGNANT BRAIN TUMORSGlobeNewsWire • 11/22/21